^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Actimmune (interferon gamma-1 b)

i
Other names: Ad-IFNg, Adenovirus-Interferon-gamma, rHu-IFN-γ
Associations
Company:
Amgen, Clinigen
Drug class:
IFNγ stimulant
Associations
7d
Safety and Efficacy of Interferon-Gamma 1b in Patients with Candidemia (clinicaltrials.gov)
P2, N=200, Recruiting, Radboud University Medical Center | Trial completion date: Jan 2025 --> Jun 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
Trial completion date • Trial primary completion date
|
Actimmune (interferon gamma-1 b)
14d
Trial primary completion date • Combination therapy
|
IFNG (Interferon, gamma)
|
Actimmune (interferon gamma-1 b)
17d
ATTAC-MCC: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (clinicaltrials.gov)
P1/2, N=7, Terminated, Fred Hutchinson Cancer Center | Trial completion date: Jan 2025 --> Jan 2024 | Active, not recruiting --> Terminated; Terminated due to insufficient funding
Trial completion date • Trial termination • Metastases • Immune cell
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR
3ms
Enrollment open • Combination therapy
|
IFNG (Interferon, gamma)
|
Actimmune (interferon gamma-1 b)
4ms
New P2 trial • Combination therapy
|
IFNG (Interferon, gamma)
|
Actimmune (interferon gamma-1 b)
8ms
ATTAC-MCC: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (clinicaltrials.gov)
P1/2, N=7, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=16 --> 7 | Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Apr 2024 --> Jan 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases • Immune cell
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR
12ms
Trial completion
|
ICAM1 (Intercellular adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
Actimmune (interferon gamma-1 b)
1year
Sting Activation Improves T-Cell Engaging Immunotherapy of Acute Myeloid Leukemia (ASH 2023)
We propose a novel mechanism by which AMG 330-activated T cells prime and sensitize AML target cells in a forward feedback loop towards STING activation, leading to increased type-I-IFN production and induction of ISGs. The beneficial effect of physiological cGAMP in enhancing AMG 330-mediated cytotoxicity was accompanied by the pronounced expression of effector cytokines and an overall cytotoxic T-cell phenotype. We established a key role for interferon gamma in AMG 330-mediated cytotoxicity of AML cells and in rendering AML cells responsive to STING agonism.
IO biomarker
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD33 (CD33 Molecule) • IL2 (Interleukin 2) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IFI16 (Interferon Gamma Inducible Protein 16) • IFNA1 (Interferon Alpha 1) • IRF7 (Interferon Regulatory Factor 7)
|
Actimmune (interferon gamma-1 b) • eluvixtamab (AMG 330)
1year
The Battle within: AML´s p53 Strategies to Evade T-Cell Attack (ASH 2023)
Bispecific T-cell recruiting antibody constructs (BsAb) have shown clinical efficacy with Blinatumomab, a CD3xCD19 BiTE® construct used for the treatment of relapsed or refractory B-cell precursor ALL...Secretome analyses indicated TGF-β as a prominent cytokine leading to an impairment of T-cell function. Further studies are needed to understand the influence of p53 on the TGF-β pathway in AML cells.
IO biomarker
|
IFNG (Interferon, gamma) • CD33 (CD33 Molecule) • IL2 (Interleukin 2) • IL18 (Interleukin 18) • TGFB1 (Transforming Growth Factor Beta 1) • CD2 (CD2 Molecule)
|
TP53 mutation • TP53 wild-type • TP53 expression
|
Blincyto (blinatumomab) • Actimmune (interferon gamma-1 b)
1year
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma (clinicaltrials.gov)
P2, N=28, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Mar 2023
Trial completion • Trial completion date • Metastases
|
IFNG (Interferon, gamma) • CTAG1B (Cancer/testis antigen 1B)
|
CTAG1B expression
|
Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b)
1year
ATTAC-MCC: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (clinicaltrials.gov)
P1/2, N=16, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2025 --> Apr 2025 | Trial primary completion date: Dec 2025 --> Apr 2024
Trial completion date • Trial primary completion date • Metastases • Immune cell
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR
over1year
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
P1, N=6, Recruiting, Sawa Ito, MD | Trial completion date: Jun 2023 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Oct 2023
Trial completion date • Trial primary completion date
|
ICAM1 (Intercellular adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
Actimmune (interferon gamma-1 b)
over1year
Trial completion date • Metastases
|
IFNG (Interferon, gamma) • CTAG1B (Cancer/testis antigen 1B)
|
CTAG1B expression
|
Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b)
over1year
MCC-18936: Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer (clinicaltrials.gov)
P1/2, N=51, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2023
Trial completion • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • Actimmune (interferon gamma-1 b)
over1year
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
P1, N=6, Recruiting, Sawa Ito, MD | Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Mar 2023 --> Jun 2023
Trial completion date • Trial primary completion date
|
ICAM1 (Intercellular adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
Actimmune (interferon gamma-1 b)
almost2years
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
P1, N=6, Recruiting, Sawa Ito, MD | Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
Trial completion date • Trial primary completion date
|
ICAM1 (Intercellular adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
Actimmune (interferon gamma-1 b)
almost2years
Pilot Trial of Interferon-γ and Donor Lymphocyte Infusion to Treat Relapsed Myeloblastic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation (TCT-ASTCT-CIBMTR 2023)
IFN-γ (Actimmune®, Horizon Therapeutics) was given as monotherapy for 4 weeks, followed by DLI and IFN-γ for up to 8 additional weeks... This is the first study to show safety and tolerability of IFN-γ in alloSCT recipients. We observed durable remissions in all patients who received IFN-γ and DLI. We are continuing to enroll in the phase I trial with a shortened IFN-γ monotherapy period and are designing a phase II multicenter trial to evaluate efficacy.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • CD34 (CD34 molecule) • ICAM1 (Intercellular adhesion molecule 1)
|
PD-L1 expression • IFNG expression
|
Actimmune (interferon gamma-1 b)
2years
Pilot Trial of IFN-γ and Donor Lymphocyte Infusion to Treat Relapsed AML and MDS after Allogeneic Hematopoietic Stem Cell Transplantation (ASH 2022)
The study had two stages: IFN-γ monotherapy (stage 1) with a fixed dose of IFN-γ (ACTIMMUNE®, Horizon Therapeutics) 100 mcg subcutaneously 3 times per week (outpatient self-injection) for 4 weeks and subsequent DLI combined with IFN-γ (stage 2) for 8 more weeks... IFN-g was safe in this pilot cohort of subjects with relapsed AML/MDS post-alloSCT. To our knowledge, this is the first time that IFN-γ has been tested on such subjects. In vivo, IFN-γ induced the predicted changes in myeloblasts.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • ICAM1 (Intercellular adhesion molecule 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
PD-L1 expression • IFNG expression
|
Actimmune (interferon gamma-1 b)
2years
Trial completion date
|
IFNG (Interferon, gamma) • CTAG1B (Cancer/testis antigen 1B)
|
CTAG1B expression
|
Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b)
over2years
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
P1, N=6, Recruiting, Sawa Ito, MD | Trial completion date: Jul 2022 --> Dec 2022 | Trial primary completion date: Jul 2022 --> Dec 2022
Trial completion date • Trial primary completion date
|
ICAM1 (Intercellular adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
Actimmune (interferon gamma-1 b)
over2years
MCC-18936: Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer (clinicaltrials.gov)
P1/2, N=51, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jun 2022 --> Jun 2023
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • Actimmune (interferon gamma-1 b)
almost3years
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
P1, N=6, Recruiting, Sawa Ito, MD | Trial completion date: Jan 2022 --> Jul 2022 | Trial primary completion date: Dec 2021 --> Jul 2022
Trial completion date • Trial primary completion date
|
IFNG (Interferon, gamma) • ICAM1 (Intercellular adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
Actimmune (interferon gamma-1 b)
over3years
Clinical • Trial termination
|
IFNG (Interferon, gamma) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • IFNA1 (Interferon Alpha 1)
|
Actimmune (interferon gamma-1 b) • ViraferonPeg (peginterferon-α-2b)
over3years
Clinical • Trial completion date
|
IFNG (Interferon, gamma) • CTAG1B (Cancer/testis antigen 1B)
|
CTAG1B expression
|
Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b)
over3years
Clinical • Enrollment open
|
IFNG (Interferon, gamma) • ICAM1 (Intercellular adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1)
|
Actimmune (interferon gamma-1 b)
almost4years
Clinical • Trial initiation date
|
IFNG (Interferon, gamma) • ICAM1 (Intercellular adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1)
|
Actimmune (interferon gamma-1 b)
almost4years
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer (clinicaltrials.gov)
P1/2, N=52, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • Actimmune (interferon gamma-1 b)
4years
Clinical • New P1 trial
|
IFNG (Interferon, gamma) • ICAM1 (Intercellular adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1)
|
Actimmune (interferon gamma-1 b)
4years
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (clinicaltrials.gov)
P1, N=18, Completed, National Cancer Institute (NCI) | Recruiting --> Completed | N=40 --> 18 | Trial completion date: Jul 2023 --> Sep 2020 | Trial primary completion date: Apr 2022 --> Sep 2020
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
IFNG (Interferon, gamma) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • IFNA1 (Interferon Alpha 1)
|
Actimmune (interferon gamma-1 b) • ViraferonPeg (peginterferon-α-2b)